Benzinga's Top Pre-Market Gainers
Aeterna Zentaris (NASDAQ: AEZS) added 4.15% to $2.26 in the pre-market session. Aeterna Zentaris granted Special Protocol Assessment by the U.S. Food and Drug Administration for Phase 3 registration trial in endometrial cancer with AEZS-108.
Arena Pharmaceuticals (NASDAQ: ARNA) moved up 1.71% to $8.94 in the pre-market session. Arena Pharmaceuticals shares have jumped 370.05% over the past 52 weeks, while the S&P 500 index has gained 12.76% in the same period.
LSI (NYSE: LSI) soared 1.61% to $7.10 in the pre-market trading. Analysts at Wunderlich initiated coverage on shares of LSI with a “buy” rating.
Marvell Technology Group (NASDAQ: MRVL) surged 1.54% to $7.25 in the pre-market session. Analysts at Wunderlich initiated coverage on shares of Marvell with a “hold” rating.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.